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Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine
derivatives: a new series of anti-proliferative agents
Marcella Coronnelloa, Giovanna Cicianib, Enrico Minia, Gabriella Guerrinib,
Barbara Caciaglia, Silvia Sellerib, Annarella Costanzob and Teresita Mazzeia
We report the synthesis and biological evaluation of a
new series of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine
derivatives (compounds 1–4) bearing appropriate
substitutions in positions 7 and/or 8. The objective of
this investigation was to study the effects of these
substitutions on the cytotoxic activity of four new
compounds against established human cancer cell lines
(i.e. HT29 and HCT-8, colon carcinoma, MCF7, breast
carcinoma, and A549, lung carcinoma cells). The inhibitory
effects of compounds 1–4 on cell growth were assessed by
the sulforhodamine B assay. Also, the effects of these
compounds on cell cycle distribution of human colon
carcinoma cells (HCT-8) were analyzed by flow cytometry.
3-Nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives
displayed IC50 values in the micromolar range on the
growth of the four cell lines tested. Cell cycle perturbations
induced on HCT-8 cells by study compounds at the IC50
values consisted prevalently of a slight accumulation of
cells in G0/G1 phase and a slight decrease in G2/M phase.
However, compound 3 induced a marked accumulation of
cells into S phase with concomitant decrease in G0/G1 and
G2/M phases. Cytotoxicity data, compared to those obtained
with 3-cyano-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (compound 5, NSC 683334) and other
compounds previously synthesized in our laboratory,
demonstrated a similar or even improved cytotoxic
potency. Cell cycle perturbations caused by these
compounds support the hypothesis that they may act
by a direct or an indirect inhibition of DNA synthesis.
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Introduction
A large number of compounds from many different
chemical classes are reported in the literature as
interfering with DNA-processing enzymes [1,2] or being
DNA-intercalating agents [1,3,4].
Some derivatives of the pyrazolo[5,1-c][1,2,4]benzotria-
zine system have been extensively studied in our
laboratory as benzodiazepine receptor ligands [5]. In a
previous paper [6] we reported some variously substi-
tuted derivatives of this system which exhibited anti-
tumor properties in vitro against leukemia cells more than
against solid tumors; the nitromoiety appeared essential
for the cytotoxic activity. Synthesis and biological
evaluation of a new series of 3-nitropyrazolo[5,1-
c][1,2,4]benzotriazine derivatives 1–4 bearing other
substitutions with electron-drawers or electron-donors
in the 7 and/or 8 position are reported here.
The aim of the present research was to investigate if
these substitutions might improve the cytotoxic activity
on solid tumors. Mitomycin C, doxorubicin and com-
pound 5 (3-cyano-8-chloropyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide) [6,7] were selected as reference
compounds. The latter compound, which we previously
synthesized [7], has been selected for anti-HIV and anti-
cancer tests at the National Cancer Institute (NCI) [8].
This compound showed remarkable anti-proliferative
activity against various human tumor cell lines (IC50s
ranging from 10–5 to 10–6M) (unpublished data, see mean
graph from the NCI [8]).
The in vitro inhibitory effects of the study compounds on
the growth of human cancer cell lines (i.e. HT29 and HCT-
8, colon carcinomas, MCF7, breast carcinoma, and A549,
lung carcinoma cells) were assessed by the sulforhodamine
(SRB) B assay [9]. Also, the effects of these compounds on
cell cycle distribution of human colon carcinoma cells
(HCT-8) were analyzed by flow cytometry [10].
Materials and methods
Chemical compounds 1–4
New compounds 1–4 were synthesized according to our
previously reported procedure [7]. The starting materials
were represented by 1-(2-nitrophenyl)-5-aminopyrazole-
4-carboxylate with the appropriate substituent on the
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phenyl ring in the 4 and 5 position. These compounds
cyclize to pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
under alkaline conditions.
After decarboxylation and nitration of the 3 position,
under standard conditions, we obtained the desired
compounds 1–4.
The structures of the new compounds and new
intermediates were confirmed by 1H nuclear magnetic
resonance and IR spectroscopy. The other experimental
data are reported in Table 1. Compounds were solubilized
in dimethylsulfoxide (DMSO) at 100 times the desired
maximum test concentration (maximum final DMSO
concentration of 0.1%; this concentration was not toxic)
and stored frozen. Compounds were then diluted with
complete media to obtain the 10 times desired final
maximum test concentration. Additional serial dilutions
were made to provide a total of five drug concentrations
plus control. Aliquots of 20 ml of these different drug
dilutions were added to the appropriate microtiter wells
already containing 180 ml of medium, resulting in the
required final drug concentrations. All chemicals were
purchased from Sigma (St Louis, MO) unless otherwise
specified.
Cell cultures
The cell lines used in this study were two human colon
carcinoma cell lines (HT29 and HCT8), one breast
carcinoma (MCF7) and one lung carcinoma (A549) cell
line, obtained from the ATCC (Rockville, MD). The
HT29, HCT8 and MCF7 cell lines were maintained in
RPMI 1640 (Euroclone, Wetherby, UK) supplemented
with 10% fetal calf serum (FCS) (Euroclone) and anti-
biotics (penicillin 100U/ml and streptomycin 100mg/ml).
The A549 cell line was maintained in F12 (Euroclone)
medium supplemented with 10% FCS and antibiotics. All
cell lines were incubated at 371C, 5% CO2/95% air and
subcultured twice weekly. The cells had similar doubling
times, varying between 20 and 25h.
Cell growth inhibition studies
Exponentially growing cells were inoculated into 96-well
microtiter plates at plating densities of 3000 cells/well.
After cell inoculation, the microtiter plates were incu-
bated at 371C, 5% CO2/95% air and 100% relative
humidity for 24 h prior to the addition of experimental
drugs. After 24 h, medium was removed and replaced with
appropriate medium containing varying doses of experi-
mental agents for 4, 24 and 72 h. After 4- and 24-h
treatments, samples were washed and incubated for an
additional 72 h in drug-free medium at 371C, 5% CO2/
95% air and 100% relative humidity. According to the
procedure described by Skehan et al. [9], the assay was
terminated by the addition of cold TCA. Cells were fixed
in situ by 10% TCA and stained by SRB solution at 0.4%
(w/v) in 1% acetic acid. After staining, unbound dye was
removed by washing 5 times with 1% acetic acid and the
plates were air dried. Bound stain was subsequently
solubilized with 10mM Tris base and the absorbance was
read on an automated plate reader at a wavelength of
540 nm. The IC50 drug concentrations resulting in a 50%
reduction in the net protein increase (as measured by
SRB staining) in control cells during the drug incubation
were determined after a 72-h exposure and at 72 h
following 4- and 24-h exposures to compounds and
subsequent washout.
Cell cycle analysis
HCT-8 cells were exposed to agents at concentrations of
the test compounds equal to IC50 of a 72-h continuous
exposure. At different times (24, 48 and 72 h), floating
cells were collected, adherent cells were trypsinized
and pooled with the floating ones, and then fixed in 70%
Table 1 Structures and chemical data of the new pyrazolo[5,1-c][1,2,4]benzotriazines
Compounds R3 R7 R8 Y Formula (MW) Melting point
a
(1C)
Recrystallization solvent Yield (%)
1 NO2 NO2 CH3 O C10H6N6O5 (290.19) 234 –
a –
2 NO2 CH3 O C10H7N5O3 (245.20) 260 EtOH 80
3 NO2 CF3 O C10H4F3N5O3 (299.18) 236 EtOH 57
4 NO2 CH3 C10H7N5O2 (229.20) 264 isopropanol 70
5 (reference compound [17]) CN Cl O
N
N
N
N
R3
R7
R8
Y
aPurified by column chromatography (cyclohexane:ethylacetate 2:1).
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ice-cold ethanol and stored at 41C. Cells were then
rehydrated in phosphate-buffered saline and stained with
propidium iodide (PI, 50 mg/ml) solution containing
RNase A (5U/ml) for 30min [10]. PI-stained cells were
analyzed for DNA content with a FACStar cell sorter
(Becton Dickinson, Mountain View, CA) equipped with
an argon ion laser (Model Innova 90; Coherent, Palo Alto,
CA) operating at 500mW output at 488 nm. The red
fluorescence emitted by PI was collected by a 620-nm
long-pass filter, recorded as a measure of the amount of
DNA-bound PI and displayed on a linear scale. Data from
20 000 cells were analyzed with forward and scattered
light, and red fluorescence was recorded with Consort 30
software. Non-cellular material was excluded from the
analysis by gating side angle and forward angle light
scattering characteristics of each sample so that we could
assume that cells with a DNA content less than 2n that
appeared during the time course were apoptotic cells.
The percentage of cells in the various cycle phases was
determined using WinMDI2.8 Windows Multiple Docu-
ment Interface Flow Cytometry Application (Cylchred
Windows 95, version 1.02).
Morphological analysis
HCT-8 cells were harvested following a 48-h exposure to
72-h IC50 values of test compounds; attached (control)
cells and detached cells were collected separately,
counted, centrifuged and suspended in 50 mg/ml PI.
After staining, morphology was determined by examining
the cytospin slides using fluorescence microscopy inter-
faced with a computerized image analysis system. The
percentage of dead floating cells was evaluated by the
Trypan blue dye exclusion test.
Results
Cell growth-inhibitory effects
Cell growth inhibition by study compounds 1–4 was
evaluated on a panel of established human tumor cell
lines: colon carcinoma cells (HCT-8, HT29), breast
carcinoma cells (MCF7) and lung carcinoma cells
(A549) as a function of exposure time and concentrations.
For comparison purposes, the cytotoxicity of doxorubicin
(DOX), mitomycin C (MMC) and 8-chloro-pyrazolo[5,1-
c][1,2,4]benzotriazine-3-carbonitrile 5-oxide (compound
5) was evaluated under the same conditions. The results
from these experiments are summarized in terms of IC50
values in Table 2 and Fig. 1.
Cytotoxicity after a 4-h exposure
After a short-term exposure, in HCT-8 and MCF7 cells
IC50 values ranged from 3.6 to 9.4 mM for all compounds,
with the exception of compound 4 in HCT-8 cells and
compound 5 in MCF7 cells (IC50>10 mM); in HT29 and
A549 cells all compounds exhibited IC50>10 mM. All cell
lines were highly sensitive to DOX and MMC, with IC50
values ranging from 0.2 and 0.5 mM.
Cytotoxicity after a 24-h exposure
After an intermediate exposure, HCT-8 cells displayed a
similar degree of sensitivity to all study compounds (IC50
values ranging from 2.3 to 4.5 mM). MCF7 cell line
exhibited IC50 values between 1.8 and 6.4 mM, but
Table 2 IC50 values (lM)
a of study compounds as determined by the SRB assay
Treatment Cell type
HCT-8 HT29 MCF7 A549
4-h exposureb
1 3.58 >10 5.29 >10
2 6.36 >10 6.09 >10
3 9.42 >10 6.5 >10
4 >10 >10 7.4 >10
5 5.84 >10 >10 >10
MMC 0.16 0.47 0.36 0.47
DOX 0.177 0.375 0.175 0.34
24-h exposureb
1 2.64 4.7 2.57 2.32
2 2.35 2.39 1.76 1.95
3 4.53 6.96 6.45 5.88
4 3.91 5.2 4.16 6.09
5 3.69 >10 >10 >10
MMC 0.077 0.06 0.066 0.11
DOX 0.129 0.089 0.088 0.12
72-h continuous exposure
1 2.08±0.78 2.67±0.36 3.64±1.1 1.64±0.2
2 1.60±0.11 2.39 2.26±0.83 1.64±0.19
3 3.16±1.00 3.43±0.55 2.08±0.29 2.32±0.72
4 3.31±0.95 3.71±0.26 4.64±0.88 4.64±0.36
5 2.75 >10 2.08 >10
MMC 0.075±0.01 0.088 0.092±0.016 0.095±0.015
DOX 0.07±0.018 0.067±0.01 0.064 0.053±0.024
aMean±SE of at least three determinations or mean of two independent experiments performed with quadruplicate cultures at each drug concentration tested.
bIC50 values after a 72-h drug washout.
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was not sensitive to compound 5 (IC50>10 mM).
Prolongation of exposure time induced a higher degree
of sensitivity to study compounds also in HT29 and A549
cells (IC50 values ranging from 2.3 to 7.0 mM), with the
exception of compound 5 (IC50>10 mM). IC50 values for
DOX and MMC ranged from 0.07 and 0.13 mM in all cell
lines.
Cytotoxicity after a 72-h exposure
After a long-term exposure, the inhibitory cell growth
effects of study compounds were similar in all cell lines
and ranged from 1.6 and 4.6 mM. HT29 and A549 cells
remained not sensitive to compound 5 (IC50>10 mM).
IC50 values for DOX and MMC ranged from 0.05 and 0.09
mM in all cell lines.
Cell cycle effects
Analysis of cell cycle perturbations induced by study
compounds was performed on a representative cell line
(HCT-8). Figure 2 shows the cell cycle effects after
exposure to 72-h IC50 values of the various study
compounds.
Continuous exposure of 24 h to compounds 1, 4 and DOX
appeared not to cause any significant cell cycle perturba-
tion. After the same exposure time, in the presence of
compound 2, a substantial accumulation of cells in the
G2/M phase was observed with a considerable decrease in
the S phase. Compound 3 and MMC caused a marked
accumulation of cells in the S phase with a notable
decrease of the G0/G1 fraction. Compound 5 did not
appear to cause any significant change in cell cycle
distribution.
At later time points (48 and 72 h) compound 4 induced a
modest accumulation of cells in G0/G1 accompanied by a
slight decrease of G2/M cells. A similar trend was
observed as far as compound 1 and DOX were concerned.
The early accumulation of cells in the G2/M phase and
S/G2/M interface noted with compound 2 and MMC at
24 h rapidly decreased at 48 h. At 72 h no substantial cell
cycle perturbations were observed with compound 2,
while a slight cell decrease in S phase and a slight cell
accumulation in G0/G1 was observed with MMC. Cell
accumulation in the S phase reported with compound 3
was instead persistent within time until 72 h. No
substantial late cell cycle effects were observed with
compound 5. With this compound only an increased slight
block of cells in the G0/G1 phase accompanied by a
modest decrease of cells in the S phase was in fact
observed at 72 h.
Morphological effects
Detached HCT8 cells were collected 48 h following
incubation with 72-h IC50s of the study compounds.
These cells showed an apoptotic morphology with
Fig. 1
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compacted and fragmented nuclei when compared with
attached control cells where the chromatin was diffuse
(Fig. 3a). Moreover, 58–80% of detached cells excluded
Trypan blue 48 h after exposure to IC50 agent values,
meaning that their membranes remained intact. Figure
3(b and c) illustrates the percentage of HCT-8 cells with
sub-G0/G1 DNA content calculated on the total cell
population 48 h after drug exposure; at this time we had a
higher number of floating cells. Spontaneous apoptosis
was observed in the 0.5% of the control cells with 16% of
cell debris. Only minimal, non-significant increases in the
percentage of HCT-8 apoptotic cells were observed with
study compounds and control drugs, ranging from 0.9 to
2.5%. On the contrary, abundant cellular debris, as
demonstrated by the DNA histograms, was present,
ranging from 27 to 41%.
Discussion
Previous investigations have already revealed favorable
cytotoxic properties for some 3-nitropyrazolo[5,1-
c][1,2,4]benzotriazine derivatives, especially against leu-
kemia cells, and low cytotoxic activity against solid
tumors [6]. This further stimulated our interest, and
thus we continued our investigation with the synthesis
and study of this new class of 3-nitropyrazolo[5,1-c]
Fig. 2
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[1,2,4]benzotriazine derivatives 1–4 bearing other sub-
stitutions with electron-drawers or electron-donors in
positions 7 and/or 8. Our data demonstrate that the new
series of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine deri-
vatives exerts cytotoxic activity at micromolar concentra-
tions against human colon, breast and lung carcinoma cell
lines. In all tumor cell lines tested, the growth-inhibitory
effects of the study compounds were dependent on both
drug concentrations and exposure times.
The differences in sensitivity to study compounds
observed in the various cell lines after a short-term
exposure (4 h) became less pronounced following longer-
term exposures (24 and 72 h). When HT29 and A549 cells
were exposed to study compounds for 4 h, 50% cell
growth inhibition was not achieved even at the highest
concentration tested (10 mM). The same result was
observed in HCT-8 and MCF7 cells with short-term
exposure to compounds 4 and 5. Increasing the exposure
time from 4 to 24 h notably decreased the IC50 values
observed for all cell lines, whereas an increase in the
exposure time from 24 to 72 h only slightly decreased the
IC50 values for the four cell lines.
We also studied the cell kinetic perturbations pro-
duced by in vitro exposure to study compounds of
one representative tumor cell line (HCT-8). At 72-h
IC50 values, this resulted in cell cycle perturbations
Fig. 3
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comparable to those of MMC and DOX, except for
compound 3 which induced a marked accumulation of
cells into the S phase with a concomitant decrease in G0/
G1 and G2/M phases.
Since apoptosis is a major mode of cell death induced by
several DNA-damaging agents [11], we evaluated the
induction of apoptosis of colon carcinoma cells (HCT-8)
treated with IC50 values of the study compounds.
Apoptotic cells were detected as the population of cells
with sub-G0/G1 DNA content. Further analysis by
fluorescent microscopy of the PI-stained detached cell
morphology helped us to confirm the presence of
apoptotic cells in the cell culture which may be the
same recorded with flow cytometry as the sub-G0/G1
DNA peak. Previous studies by other authors have shown
that only detached cells exhibit apoptotic morphology,
while attached treated cells have a morphology similar to
that of attached untreated control cells [12–14].
Our results indicate the presence of a modest percentage
(up to 2.5%) of cells with sub-G0/G1 DNA content in all
samples after a 48-h exposure to agents. On the other
hand, the presence of abundant cellular debris, provided
by the DNA histograms, suggests cell killing. One
possible explanation is that all compounds induce
extensive fragmentation of DNA, generating very small
DNA fragments or single nucleotides that cannot be
detected with flow cytometry.
In conclusion, this study has demonstrated that 3-
nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives pos-
sess cytotoxic activity in the micromolar range against
human tumor cell lines under aerobic conditions.
This activity is similar or even improved as compared
to 3-cyano-8-chloropyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide 5, previously synthesized in our laboratory, but
significantly lower than that of DOX and MMC. The
effects on the cell cycle induced by the 3-nitropyrazo-
lo[5,1-c][1,2,4]benzotriazine derivatives were, however,
similar to those of DOX (e.g. compounds 1, 3 and 4) and
MMC (e.g. compounds 2 and 5). These results do not
necessarily imply that the cytotoxic mechanism of the
tested compounds is similar to that of DOX or MMC, but
the structural features of these agents suggest that
DNA may be one of the targets of their cytotoxic
action. Although these data do not provide an explanation
for the anti-proliferative effects of 3-nitropyrazolo[5,1-c]
[1,2,4]benzotriazine derivatives, they confirm the critical
role of the nitro group on cytotoxicity independently of
substituents in positions 7 and 8. These results warrant
further investigations to clarify pathways through which
alterations of the cell cycle lead to cell growth inhibition.
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